A phase 2 study to assess the safety and efficacy of FLX475 (tivumecirnon) combined with pembrolizumab in patients with advanced or metastatic gastric cancer.

Do‐Youn Oh, Young Su Noh, Jun‐Eul Hwang et al.|Journal of Clinical Oncology|2025

Cited by 0